Metformina

Metformin Hydrochloride, the active ingredient in Metformina, is a Biguanide presented as an oral tablet for oral use. It is used to lower blood glucose in adults with type 2 diabetes mellitus, improving insulin sensitivity and reducing hepatic glucose output to help achieve glycemic control.

GNH USA supplies Metformina as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Metformina (metformin hydrochloride) is indicated for conditions within the type 2 diabetes therapeutic pathway.

Type 2 diabetes mellitus: improves glycemic control by decreasing hepatic glucose production and enhancing peripheral insulin sensitivity.

Metformina may be associated with a range of adverse reactions, which are categorized by frequency.

Common Side Effects: - Nausea: mild to moderate stomach upset, often transient. - Diarrhea: loose stools that may occur early in therapy. - Abdominal discomfort: cramping or bloating. - Metallic taste: transient alteration in taste perception. - Decreased appetite: reduced desire to eat. - Weight loss: modest reduction in body weight.

Serious or Rare Side Effects: - Lactic acidosis: a rare but life‑threatening accumulation of lactate. - Severe skin reactions: such as Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Vitamin B12 deficiency: may develop with long‑term use. - Hepatic failure: rare impairment of liver function. - Pancreatitis: inflammation of the pancreas, presenting with abdominal pain.

When prescribing Metformina, clinicians should consider several safety measures.

Renal function assessment: evaluate creatinine clearance before initiating therapy. Hepatic function monitoring: avoid use in patients with significant liver disease. Risk of lactic acidosis: contraindicated in severe renal impairment, acute heart failure, or conditions predisposing to hypoxia. Elderly patients: start at lower doses and monitor for accumulation. Alcohol consumption: advise patients to limit intake to reduce lactic acidosis risk. Store below 25°C: keep in the original pack, protect from moisture.

Metformina can interact with other medicines, influencing its efficacy or safety.

Major Interactions (Avoid): - Iodinated contrast agents: may precipitate acute renal failure and increase lactic acidosis risk. - Cimetidine: can raise metformin plasma concentrations. - Alcohol: potentiates the risk of lactic acidosis. - Renal‑impairing drugs (e.g., NSAIDs): may reduce metformin clearance. - Carbamazepine: may decrease metformin effectiveness.

Moderate Interactions (Monitor Closely): - Beta‑blockers: may mask hypoglycemia symptoms. - Thiazide diuretics: can enhance hypoglycemic effect. - ACE inhibitors or ARBs: may affect renal function, requiring dose adjustment. - Corticosteroids: may increase blood glucose, necessitating closer monitoring. - Oral contraceptives: may slightly raise metformin levels.